Puma Biotechnology Inc (PBYI)

68.08
NYSE : Health Care
Prev Close 65.98
Day Low/High 66.06 / 69.51
52 Wk Low/High 19.74 / 94.92
Avg Volume 807.50K
Exchange NYSE
Shares Outstanding 32.49M
Market Cap 2.14B
EPS -7.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.

Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology

Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology

Cramer says he's still a believer in Salesforce and its CEO, Marc Benioff, despite the last quarter's results.

Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?

Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?

Cramer said the market is a ball of confusion and he doesn't blame any investor for sitting on the sidelines a while.

Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI

Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology, Inc. , where a total volume of 3,028 contracts has been traded thus far today, a contract volume which is representative of approximately 302,800 underlying shares (given that every 1 contract represents 100 underlying shares).

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines Agency (EMA).

Puma Biotechnology Reports Second Quarter 2016 Financial Results

Puma Biotechnology Reports Second Quarter 2016 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016.

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Morning Movers: GE, AMD, P, PBYI

Morning Movers: GE, AMD, P, PBYI

General Electic shares dipped as industrial orders waned in the second quarter.

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of...

Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.

Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine

Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant treatment of breast cancer were published in...

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

'Mad Money' Lightning Round: I Like Sirius XM Radio

'Mad Money' Lightning Round: I Like Sirius XM Radio

Cramer is taking Southwest Airlines over United Continental while Palo Alto Networks is good value but not great.

Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG

Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG

Three of Cramer's four FANG stocks still perform but the fourth can easily be replaced by these two companies.

Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for neratinib.

August 19th Options Now Available For Puma Biotechnology (PBYI)

August 19th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 19th expiration.

Short Interest Increases 11.8% For PBYI

Short Interest Increases 11.8% For PBYI

The most recent short interest data has been released for the 05/31/2016 settlement date, which shows a 530,564 share increase in total short interest for Puma Biotechnology, Inc. , to 5,028,719, an increase of 11.80% since 05/13/2016.

Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting

Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer.

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO)...

Puma Biotechnology To Present At UBS Global Healthcare Conference

Puma Biotechnology To Present At UBS Global Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

July 1st Options Now Available For Puma Biotechnology (PBYI)

July 1st Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the July 1st expiration.

Puma Biotechnology Reports First Quarter 2016 Financial Results

Puma Biotechnology Reports First Quarter 2016 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016

Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American Association for Cancer Research (AACR) Annual...

Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology

Puma Biotechnology's NEfERT-T Phase II Study Published Online In JAMA Oncology

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in...

Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application

Puma Biotechnology (PBYI) Stock Plunges on Delayed Marketing Application

Puma Biotechnology (PBYI) stock is lower in early-morning trading on Tuesday after the company announced that it will delay filing its New Drug Application (NDA) for a breast cancer drug.

Puma Biotechnology Updates Timeline For Filing New Drug Application

Puma Biotechnology Updates Timeline For Filing New Drug Application

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.